

Rheumatology	Proposed Split	Avg / Infusion	Monthly	Annualized	Scenario 2 Monthly	Scenario 2 Annualized
Net Revenue	Note 1 & 2	\$ 13,898	\$ 1,389,819	\$ 16,677,827	6,949,095	83,389,137
Drug Cost	Note 1 & 2	11,242	1,124,154	13,489,853	5,620,772	67,449,264
Supply Cost	Note 1 & 2	380	38,000	456,000	190,000	2,280,000
Nursing / Admin Cost	Note 1 & 2	238	23,800	285,600	119,000	1,428,000
Total operating expenses			1,185,954	14,231,453	5,929,772	71,157,264
Gross Margin \$		2,039	203,865	2,446,375	1,019,323	12,231,873
Gross Margin %			14.7%	14.7%	14.7%	14.7%
Profit Share						
Rheumatology	50%	1,019	101,932	1,223,187	509,661	6,115,937
SSRX	50%	1,019	101,932	1,223,187	509,661	6,115,937
Infusion Counts / Mo	Note 1		100	1,200	500	6,000
Average Rev / Count				13,898	\$	13,898
Number of Months			1		1	
Patients / Month*			100.00		500.00	
Payors*			8		8	

Note:

- 1 - Assumes one patient per infusion per payor per drug provided
- 2 - Medicare Rates are used as a default rate for payors we have no data
- 3 - Stelara runs through RX30 Only
- 4 - Rates are based existitng Clients averages

Infusion Count- Monthly (not factoring growth)	Pt Cnt	Rev	Profit Share	
			Client	SSRX
Month 1	100	1,389,819	101,932	101,932
Month 2	100	1,389,819	101,932	101,932
Month 3	100	1,389,819	101,932	101,932
Month 4	100	1,389,819	101,932	101,932
Month 5	100	1,389,819	101,932	101,932
Month 6	100	1,389,819	101,932	101,932
Month 7	100	1,389,819	101,932	101,932
Month 8	100	1,389,819	101,932	101,932
Month 9	100	1,389,819	101,932	101,932
Month 10	100	1,389,819	101,932	101,932
Month 11	100	1,389,819	101,932	101,932
Month 12	100	1,389,819	101,932	101,932
	1,200	16,677,827	1,223,187	1,223,187